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Summary Prognostic information is essential for the evaluation, judgement and optimal treatment of patients
with squamous cell cancers (SCCs) of the upper aerodigestive tract. Using immunohistochemical and flow
cytometric techniques, we have studied the significance of cellular expression of the Ki-67 antigen, epidermal
growth factor receptor (EGFR), the transferrin receptor (TFR) and DNA ploidy status in a prospective
analysis of patients with SCCs of the head and neck region. All 42 fresh tumour samples (five well
differentiated; 28 moderately differentiated; nine poorly differentiated) expressed both EGFR and TFR to
varying degrees. Receptor expression was most marked on the peripheral invading margin of cancer cell
islands although staining was also demonstrated in a random fashion within cellular islands and consistently
along the basal cell layer of overlying stratified squamous epithelium. The percentage of cancer cells that
reacted with the Ki-67 monoclonal antibody was assessed as low (< 10%) in 15 samples (35.8%), intermediate
(10-30%) in 19 samples (45.2%) and high (>30%) in eight samples (19.0%). Eleven of 15 samples (73%)
with a low percentage reactivity were DNA diploid, whereas seven of eight samples (87.5%) with a high
percentage reactivity were DNA aneuploid. Poorly differentiated SCCs were significantly more often aneuploid
than were either moderately or well differentiated tumours. Our results suggest that EGFR and TFR are
widely distributed on SCCs, especially on proliferating cells at the invading tumour margin. In addition, there
is a close spatial correlation between cells expressing EGFR, TFR and those expressing the Ki-67 antigen.
Tumours in which the staining intensity for both EGFR and TFR was intense invariably expressed the Ki-67
antigen in a high proportion of cells. Further patient follow-up will be important in determining whether
intense EGFR and TFR staining, combined with a high percentage reactivity with Ki-67 antibody and DNA
aneuploidy, will ultimately define a subset of head and neck cancer patients with a poor clinical outcome.
Squamous cell cancers (SCCs) of the upper aerodigestive
tract represent 5% of newly diagnosed cancers in the
Western world (Schneiderman, 1978). Traditional therapy
with surgery and/or radiotherapy can be curative in patients
with relatively early stage disease. However, early and late
morbidity from the functional, cosmetic and socio-economic
impact of treatment can significantly impair the patient's
quality of life. Furthermore, incurable disease following
treatment almost invariably remains localised in the head and
neck region so that terminal suffering is often protracted and
distressing.
The clinical observation that patients with head and neck
SCCs in comparable stages may have diverse clinical courses
and responses to similar treatments is, as yet, unexplained.
Although clinical outcome is influenced by stage of disease at
presentation (Zarbo & Crissman, 1988), the TNM (UICC
staging) system is an imperfect prognostic indicator.
Similarly, routine histomorphic grading systems and
pathological appearances are of some benefit to the clinician
in predicting clinical outcome (Fletcher, 1980). Grading of
SCCs is meaningful, although not the main determinant
upon which treatment is based. Indeed, pathological criteria
are subjective, often poorly standardised and must be
regarded as relatively crude approximations of tumour cell
kinetics and biological behaviour.
Evidence from several sources suggests that the degree of
cellular proliferation within tumours holds some promise of
enabling an estimate of their biological aggression (Young et
al., 1987; Sledge et al., 1988). Estimation of the labelling
index (LI) by in vitro incorporation by tumour fragments of
tritiated thymidine has been a reliable, albeit long and
tedious, technique which has yielded important information
in many types of cancer, confirming the clinical wisdom that
fast growing cancers are more rapidly fatal than slowly grow-
ing ones (Tubiana & Courdi, 1989). For patients with breast
cancer, it has been suggested that the number of mitotic
figures present is the most important prognostic variable
(Tubiana et al., 1989).
The advent of monoclonal antibodies to various cellular
antigens, oncogenes and oncoproteins has provided a novel,
relatively quick, reproducible and simple means of studying
various characteristics of the malignant phenotype. The Ki-
67 monoclonal antibody recognises a nuclear antigen present
in proliferating cells, but absent in resting cells (Gerdes et al.,
1983). Since its original description by Gerdes et al. (1983),
Ki-67 antibody has been a valuable tool for estimating the
proportion of proliferating cells in a number of tumour types
(Gerdes et al., 1986; Shepherd et al., 1988). Gerdes' group
has recently demonstrated a highly significant correlation
between the proportion of Ki-67 positive cells and the histo-
logic classification of lymphomas into high and low grade
malignancies (Gerdes et al., 1984).
Enhanced expression of epidermal growth factor receptors
and transferrin receptors is known to be associated with
cellular proliferation (Osborne et al., 1982; Trowbridge &
Omary, 1981). The EGF receptor is a 170kDa transmem-
brane glycoprotein whose function is to bind the mitogen
EGF and to transduce this signal across the cell membrane
to the cytoplasm (King, 1985; Marks, 1987). Immunohisto-
chemical studies have demonstrated EGF receptor expression
in the basal cell layer of normal squamous epithelia, and high
levels of EGF receptor expression have been identified in
certain tumour types, sometimes associated with
amplification of the EGF receptor gene (Stoscheck & King,
1986). Several authors have recently reported a correlation
between EGFR expression and poorer differentiated, more
proliferative and invasive tumours (Sainsbury et al., 1985). It
is possible that receptor amplification results from local pro-
duction of EGF or EGF-like proteins (Derynck et al., 1987)
which enhance EGFR expression (Earp et al., 1986). The
presence of EGFR overexpression is recognised as a hall-
mark of SCCs (Yamamoto et al., 1986, and in lung cancer
can be of diagnostic value in distinguis} ing SCCs from non-
SCC histologies. High intensity EGFR staining may also
define more invasive subpopulations of SCC (Veale et al.,
1987).
The TF receptor is a transmembrane glycoprotein capable
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of binding transferrin molecules, essential for various intra-
cellular enzyme systems (Newman et al., 1982). TF receptors
have a widespread distribution and have been described in
various cell populations in vitro and in vivo (Sutherland et al.,
1981; Shindelman et al., 1981). Expression of TF receptors
appears to correlate with proliferation and/or activated cell
metabolism (Shindelman et al., 1981), whereas cells or tissues
in a resting state do not express the transferrin binding
protein on their cell membranes (Wada et al., 1979).
Immunohistochemical analysis has demonstrated intense TF
receptor expression in many carcinomas and in a limited
number of noirnal tissues (Gatter et al., 1983); in some, a
correlation between TF receptor expression and tumour
grade or stage has been established (Wrba et al., 1989).
In contrast to the subjectivity associated with currently
used prognostic criteria, analysis of solid tumours by flow
cytometry (FCM) permits rapid, objective and quantitative
evaluation of cellular DNA content (Merkel et al., 1987).
Abnormal cellular DNA content (aneuploidy), a reflection of
chromosomal instability, is a well-recognised and common
feature of human cancer, and ploidy status appears to be an
important determinant of clinical outcome at a number of
cancer sites (Friedlander et al., 1984; Merkel et al., 1987). In
addition to measuring DNA content, FCM also allows some
assessment of cellular proliferation activity (S-phase content),
which may add a new dimension to current clinical and
pathological classifications of malignancy. Hedley et al.
(1983) have described an innovative technique which enables
analysis of single cell nuclear suspensions using formalin-
fixed paraffin-embedded tissue and which yields FCM profiles
very close to those obtained from analysis of fresh tissue.
In the present study, we have used three monoclonal
antibodies (Ki-67, EGFR, TFR) to assess the frequency and
significance of cellular proliferation marker expression in
SCCs of the head and neck region. In addition, we have
determined the ploidy status of the same patients and
attempted to relate ploidy status to histological grade and
level of proliferation marker expression in an attempt to
improve the predictability of disease outcome.
Materials and methods
Fresh tumour samples were obtained from primary sites (oral
cavity 26, larynx 10, pharynx 6) in 42 newly diagnosed
patients with squamous cell head and neck cancers (30 male,
12 female) undergoing surgery or diagnostic endoscopy.
Patients had a mean age of 66.8 years (range 46-82 years).
Tumour samples from the operation theatre were frozen in
liquid nitrogen in all patients within 30 min of resection. At
the time of immunohistochemistry, samples of the frozen
tissue were embedded in Tissue-Tek OCT (Miles Scientific,
Naperville, IL, USA) and were maintained at - 700C. His-
tological grading was performed by R.C. on paraffin sections
of the same tumour. There was a range of patterns within
each tumour. When there was predominantly keratinisation
with squamous epithelial pearls, the tumour was graded as
well differentiated. When keratinisation was present only in
some areas of the tumour it was graded as poorly
differentiated. When there appeared to be a fairly even mix-
ture of keratinising areas and non-keratinising areas, the
tumour was graded as moderately well differentiated. Some
keratinisation was present in all of the tumours studied.
Immunohistochemistry
The Ki-67 antigen, EGF and TF receptors were identified by
means of an indirect immunoperoxidase technique with
murine monoclonal antibodies as previously described (Hsu
et al., 1981). The EGF receptor monoclonal antibody was
raised from an epidermoid carcinoma cell line (A431) which
expresses a high concentration of EGF receptors (Waterfield
et al., 1982). The monoclonal antibodies to Ki-67 and to the
transferrin receptor (HuLy-im9) were available commercially
(Dako Immunoglobulins, Copenhagen and Australian
Monoclonal Development Co., respectively). The HuLy-m9 antibody has a specificity equivalent to that of monoclonal
antibody OKT9 (Panaccio et al., 1986).
Fifteen micrometre cryostat sections were cut and picked
up on gelatine-coated slides. After drying at room
temperature (RT), sections were covered with 5% horse
serum in PBS as a blocking agent for 10 min. Sections were
then incubated at RT with appropriate dilutions of the
primary antibody (Ki-67 1:30; EGFR 1:300; TFR 1:1,000) for 30 min. Sections were then washed twice in PBS and
incubated with biotinylated horse anti-mouse immuno-
globulin for 30min, followed by a further 5 min wash in PBS
and then a 30 min incubation with Vector ABC reagent (Vector Labs, Burlingame, CA, USA). After two further
5 min washes in PBS, peroxidase activity was developed by
means of a solution of 3,3-diaminobenzidine (1 mgml-') with 0.08% v/v H202.
Sections were washed in water, counterstained with
haematoxylin, dehydrated and mounted. Sections of human
placenta which contains large amounts of EGF receptor and
TF receptor were used as positive controls. Negative controls
were incubated with an irrelevant murine antibody in the first
step and were then treated as described above.
Immunohistochemical assessment
The staining intensity for EGFR and TFR was assessed by two observers reading the sections independently without
prior knowledge of the clinical and pathological features of
the tumours. The sections were graded on a scale from 1 +
to 3 + according to the intensity of staining of malignant cells relative to the positive control. Placental controls
stained strongly positive on all occasions and showed no
staining when the irrelevant murine monoclonal antibody
was substituted.
Assessment of the Ki-67 determined proliferative tumour
cell fraction was performed on an Olympus microscope using
an ocular magnification of x 40 with an eyepiece grid (Graticules Ltd, UK). Ten to 20 fields per tumour were
examined depending on its cellularity (minimum 1,000
tumour cells). Given the assignment ofimmunohistochemical
results to several broad categories (Table I), complete agree- ment between assessors was achieved for all samples.
Flow cytometry
Two to five 50 lim sections from each paraffin block were
processed into single-cell suspensions using a modification of
the method described by Hedley et al. (1983). Dewaxing was
carried out in xylene (twice) for 10min, followed by ethanol
dehydration and progressive rehydration using 10min inter-
vals for 100%, 95%, 70% and 50% ethanol, then water. The
samples were vortexed during rehydration and centrifuged (300g, 1 min) after each step to minimise cell loss. Cells were then resuspended and incubated for 30 min at 37°C in 3 ml of
0.5% pepsin (Sigma) in 0.9% NaCI adjusted to pH 1.5 with a
few drops of 2N HCI. The resultant suspension was then
filtered through 60 micron mesh, stained for DNA with
0.1 mg m1' propidium iodide (Sigma) and 0.1 mgml-' ribonuclease A (Sigma) for 15 min before being analysed in a
flow cytometer (Becton-Dickinson FACS IV) equipped with
an argon ion laser operating at 200 mW at 488 nm. All
tumour samples contained DNA diploid cellular components which served as an internal diploid standard. Non-diploid cell populations were defined by the presence of discrete Gl, GO populations differing from diploid by at least 10%.
The percentage S-phase cells could be determined reliably from the computer program in all 19 diploid samples but in
very few aneuploid ones because of (a) significant overlap between an aneuploid peak and the remainder of the profile, (b) the presence of a small aneuploid peak, (c) multiple aneuploid peaks and (d) excessive cellular debris. In many
cases, more than one of the above situations applied. Because
of the relatively high incidence of aneuploidy in our samples (54%, see below), the above mentioned technical limitationsCELLULAR PROLIFERATION MARKERS 823
Table I Relationship between histological grade, EGFR, TFR, Ki-67 monoclonal reactivity and ploidy
status
EGFR TFR % Ki-67 DNA ploidy
Diffn No. +/+ + + + + +/+ + + + + <10 10-30 >30 D A
WD 5 5 - 5 - 5 - - 5
MD 28 24 3 24 3 8 15 5 12 16
PD 9 5 4 5 4 2 4 3 2 7
and our small sample sizes, we chose not to further pursue
the estimation of percentage cells in S-phase by FCM for this
study.
Results
Of the 42 SCCs, five were well differentiated (WD), 28 were
moderately differentiated (MD) and nine were poorly
differentiated (PD).
Transferrin receptor (TFR)
All SCCs expressed the TFR. Variations in staining intensity
between different tumours was generally only slight, although
seven samples (4 PD; 3 MD) demonstrated markedly intense
generalised staining. The immunoreactivity was usually both
membranous and cytoplasmic in location, but was often
sufficiently intense and diffusely cytoplasmic that individual
cell borders were virtually indiscernible (Figure 1). In almost
all cases, the staining reaction was clearly more intense in
tumour cells at the invading margin, at the margins of
trabeculae and at the very periphery of invading cellular
islands. This differential spatial staining intensity was most
obvious in four of the five well differentiated tumours in
which there was a marked difference between peripheral
positively staining cells and a central clear (often totally
unreactive) central core of keratinising squamous cancer
cells. In histologically low grade SCCs, TFR expression was
more commonly membrane-bound than cytoplasmic.
Except for consistent staining in the basal cell layer and in
scattered cells of the immediate suprabasal layer, little or no
staining occurred on cells from normal (overlying) stratified
squamous epithelium. The relationship between TFR
positivity and histological grade is shown in Table I.
Epidermal growthfactor receptor (EGFR)
Staining for the EGFR was generally of similar degree and
intensity to that demonstrated for the TFR expression. As
was the case with TFR expression, all SCCs studied demon-
strated EGFR expression to varying degrees. Normal (overly-
ing) stratified squamous epithelium also demonstrated consis-
tent expression of EGFR in the basal cell laye'r and
membranous staining of scattered cells in the immediate
suprabasal layer. There was only slight variation in staining
intensity between different tumours apart from the same
seven samples which demonstrated marked generalised TFR
intensity. Immunoreactivity was often both cytoplasmic and
membrane-bound, although in the more differentiated
tumours a marked honeycomb pattern was seen in many
cases. In samples which showed moderate to intense degrees
of staining intensity, the staining was often more cytoplasmic
than membrane-bound. The staining reaction was invariably
most intense in cells at the invading tumour margin and in
cells at the periphery of invading cellular islands (Figure 2).
This was just as noticeable for the EGFR as it was for the
TFR.
The relationship between EGFR reactivity and histologic
grade is seen in Table L
Ki-67 monoclonal antibody
Figure 3 shows the relationship between nuclear reactivity
obtained with Ki-67 antibody in cases with a low (0-10%),
intermediate (10-30%) and high (>30%) growth fraction,
and histological grade. Table I demonstrates the relationships
between histologic grade and reactivity with Ki-67, EGFR
and TFR monoclonal antibodies. Between individual cases
the percentage oflabelled nuclei varied widely from 2 to 52%
(Figure 3). Heterogeneity was a feature and in some tumours
clustering of positively stained nuclei was present alongside
variably sized negative areas; in a small number of sections,
reactive nuclei were uniformly distributed throughout the
section and in a few, cytoplasmic staining 'was seen without
nuclear reactivity. In many cases it was noticeable that the
number of stained nuclei was highest around the periphery of
invading tumour islands and along trabecular margins
(Figure 4). Five well-differentiated specimens demonstrated a
consistently low reactivity, both in the region of keratin
whorls and along invading cellular margins. In a small
number of samples of high grade histology, there was a clear
correlation between a large number of nuclei expressing the
Ki-67 antigen and intense staining for both EGFR and TFR.
Flow cytometry analyses
A DNA histogram with an aneuploid Gl/G2 peak was seen
in 23 of the 42 specimens (54%). Multiple aneuploid peaks
were seen in two cases, but no hypodiploid peaks were seen.
The mean coefficient of variation (CV) for all samples was
4.7% (range 2.9-7.6%).
Figure 3 demonstrates the relationship between Ki-67
positivity, histological grade and ploidy status. All five
patients with well differentiated tumours were DNA diploid,
whereas seven of nine patients (77.8%) with poorly
differentiated tumours demonstrated a DNA aneuploid stem
line in their flow cytometric profile. Sixteen of 28 patients
with moderately differentiated SCCs (57.1%) were considered
to be aneuploid. Aneuploidy were present in seven of eight
patients with >30% Ki-67 positive cells (87.5%) and in 12
of 19 patients with 10-30% Ki-67 positive cells (63.1%).
Table I demonstrates the relationship between ploidy
status, histologic grade and monoclonal antibody immuno-
reactivity.
Discussion
Our results lend support to previous suggestions that indices
of cellular proliferation within some cancers can define
subsets of patients who have widely variable clinical out-
comes (Tubiana & Courdi, 1989). There have been so few
similar studies to ours performed on head and neck SCCs
that extrapolation of results from other solid tumours, is
necessary. An assessment of proliferative status has been
demonstrated to be a powerful prognostic index in breast,
ovarian, lung, bladder cancers, non-Hodgkin's lymphoma,
neuroblastomas and, to a lesser extent, in patients with
cancers of the head and neck, cervix and colorectum
(Tubiana & Courdi, 1989). Proliferative status has been most
commonly studied in patients with breast cancer for whom it
can be shown that a high proliferative rate is strongly linked
not only to a short relapse-free and overall survival (Tubiana
et al., 1989), but also to other conventional prognostic fac-
tors such as poor histological grade, oestrogen receptor
negativity and DNA aneuploidy (McGurrin et al., 1987;
Wrba et al., 1989). Most recently, Bouzubar et al. (1989) have demonstrated Ki-67 immunostaining most frequently in
poorly differentiated breast tumours showing high rates of824 J.H. KEARSLEY et al.
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Figure 1 a, Diffuse positive staining of invading SCC island with TFR monoclonal antibody (x 200). b, Predominantly peripheral staining with TFR monoclonal and less reactive central zones in a more differentiated SCC (x 240).
mitotic activity. Many studies have now confirmed the
adverse prognosis associated with cancers which have a high
proliferative status, and the proliferative rate is generally held
to be higher in metastases than in primary tumours of the
same histology (Tubiana & Courdi, 1989). In their study of
the relationship of ploidy status, TFR and EGFR reactivity
in breast cancer patients, Walker and Camplejohn (1986)
demonstrated significant relationships between (a) DNA
ploidy and percentage S-phase cells, (b) the degree of histo-
logic differentiation and S-phase content and (c) the degree
of TFR and EGFR expression and both ploidy status and
S-phase fraction.
One of the few papers published on proliferation status in
head and neck SCC patients concluded that patients with a
tumour labelling index (LI) greater than 15.5% had a
significantly poorer survival than patients with a lower
tumour LI (P = 0.008) (Chauvel et al., 1989). Their results
demonstrate that a high tumour proliferation rate is an
additional independent prognostic factor in this disease.
Whether ploidy is a prognostic factor independent of other
proliferation indices is currently unknown. In the case of
breast cancer, several studies have now demonstrated that
ploidy status and proliferation indices are independent prog-
nostic factors (Hedley et al., 1987), suggesting that the
clinicopathologic features which correlate with a high pro-
liferative rate are all related to an underlying degree of
structural or functional genetic instability. A number of
relatively small studies dealing with SCC head and neck
patients have already built up a formidable body of research
opinion suggesting that patients with aneuploid SCCs suffer
earlier disease relapse and die more quickly than do patients
with diploid tumours (Goldsmith et al., 1987; Johnson et al.,
1985). De Braud et al. (1988) have recently reported the
results of a prospective study of ploidy status in patients with
advanced resectable head and neck SCCs. Their results dem-
onstrate a significantly more favourable outlook in terms of
relapse-free and overall survival for patients with diploid
tumours. In our study, a number of factors hindered reliable
assessment of percentage S-phase fraction of cells. We were
able to obtain reliable estimates on relatively few specimens
because aneuploidy was common and individual aneuploid
peaks were often small compared to the height of the mainCELLULAR PROLIFERATION MARKERS 825 Jl||1|1RI_4~~~~~~~~~~~~~.;.k.....S
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Figure 2 Characteristic reactivity of SCC with EGFR mono-
clonal antibody (x 140).
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Figure 3 Relationship between percentage reactivity with Ki-67
antibody, histological grade and ploidy status. * diploid,
0 aneuploid.
Figure 4 Invasive trabeculae of SCC demonstrating a pre-
dominantly peripheral distribution of Ki-67 positive nuclei
(black) (x 180).
(diploid) GI peak. This variable and possibly inaccurate
derivation of S-phase fraction from FCM has been noted by
others (Hedley et al., 1987) and in the interests of scientific
accuracy, we chose not to pursue the issue further.
Well differentiated SCCs are characterised by proliferative
cells at the periphery of the tumour and keratinised
differentiated cells towards the centre (Ferenczy, 1982).
Previous studies using tritiated thymidine on the KLN-205
mouse SCC lung tumour model have demonstrated that the
tumour periphery is composed of highly proliferative
primitive cells which are the progenitors of the more
differentiated cells in the central portion of the tumour (Wil-
liams & Nettesheim, 1973). In their study of Ki-67 reactivity
in patients with cervical SCCs, Brown et al. (1988) noted that
the distribution of nuclear labelling varied from little to nil in
central areas of cellular maturation and keratinisation to
significantly high reactivity in the more actively proliferating
peripheral portions. The same finding in our study was so
striking that it is tempting to suggest that quantitation of the
proportion ofpositively staining cells on the invading tumour
margin may be a more significant prognostic guideline than
an overall estimate of the proportion of Ki-67 positive cells
in a given tumour.
Demonstration of the EGFR or the TFR in oral SCCs is
clearly of limited value. Previous studies have already demon-
strated that TFRs are widely distributed on the surface of
many types of cancer cells (Gatter et al., 1983), and that the
over-expression of EGFR is a hallmark associated with SCCs
(Merlino et al., 1985). It is, however, worth reiterating that
cells which strongly expressed the EGFR and TFR in our
study invariably exhibited a high reactivity with the Ki-67
monoclonal antibody. Furthermore, there was a close spatial
co-localisation of cells which expressed all three antigens.
Our observation is consistent with the finding that expression
of EGFR and TFR is found on actively divided cells and
that the most actively proliferating cells occur on the
periphery of invading tongues and islands of tumour tissue.826 J.H. KEARSLEY et al.
It is a reasonable postulate that those cells which are most
actively invasive (i.e. proliferating) will express EGFR and
TFR to the greatest extent. This is consistent with the strong
correlation between Ki-67 immunoreactivity and TFR ex-
pression in a large study of breast carcinomas (Wrba et al.,
1989). These conclusions illustrate the advantages of
immunohistochemical detection techniques relative to con-
ventional radioligand binding quantitation. While not able to
give quantitative estimates, immunohistochemistry reveals
spatial correlations and permits detection of small popula-
tions of marker positive cells. Notwithstanding this, Sains-
bury et al. (1985) have reported correlation between EGFR
content of tumours as measured by radioligand binding and
by immunohistochemistry with the monoclonal antibody
used here.
Viac et al. (1987) have already demonstrated that mapping
of TFR and EGFR showed similar and correlative distribu-
tion, and concluded that enhanced expression of EGFR and
TFR were signs of cellular stimulation. Because of the close
spatial relationship between EGFR and TFR, some reports
have suggested that the cycling of TFRs might be regulated
by EGF (Wiley & Kaplan, 1984). It is known that the
binding of mitogenic growth factors to their specific receptors
rapidly modulates surface TFR display, and it seems prob-
able that these effects on TFR expression reflect biochemical
events involved in growth factor signal transduction. In work
recently reported by Castagnola et al. (1987), EGF binding
to KB cells was followed by a similar rapid increase in
surface TFR expression and caused a modest acceleration of
cell growth. By using anti-EGFR antibodies, Castagnola
demonstrated that EGF-induced modulation of the TFR
expression required EGFR activation and subsequent auto-
phosphorylation. EGF has been reported to alter rapidly and
transiently the number of surface TFRs in normal and in
transformed epithelial cells. In some cell lines, observed
changes in TFR display following EGF exposure have been
due to altered receptor distribution and not to changes in
ligand affinity or total cellular transferrin receptor pools.
After exposure to EGF, only some cell lines demonstrate
increased TFR phosphorylation. Early responses to EGF
appear to differ with the cell type and correlate poorly with
alterations in TFR phosphorylation. Their results suggest
that TFR phosphorylation does not regulate TFR display in
all cells.
In any prospective study of head and neck SCCs, those
graded as moderately differentiated will dominate in number.
However, the designation that a tumour is moderately
differentiated is of little, if any, prognostic value to the
clinician, and our results highlight the great variation in
proliferative status among these patients. As in our study,
Walker and Camplejohn's (1986) ability to correlate expres-
sion of surface receptors with the degree of histological
differentiation was somewhat confounded by the pre-
dominance of moderately differentiated tumours and a very
small number of well differentiated ones. In the study by
Sainsbury et al. (1985), however, moderately differentiated
breast cancers comprised a smaller proportion ofcases, and a
clear cut correlation between EGFR expression and poorly
differentiated grading was demonstrated. Furthermore, Fitz-
patrick et al. (1984) observed that the highest quantities of
EGF binding sites were expressed in tumours that lacked
oestrogen receptors - a factor known to be associated with
aneuploidy, a high S-phase content and poorer
differentiation.
Neal et al. (1985) demonstrated that intense EGFR stain-
ing was related to poor differentiation of bladder cancers.
The work of Veale et al. (1987) was also confounded by a
very small number of well differentiated squamous lung
cancers and failed to demonstrate any significant relationship
between EGFR staining and degree of differentiation. How-
ever, they were able to demonstrate significantly stronger
staining in 30 stage 3 tumours compared to 47 stage 1 and 2
tumours, and they suggested that the presence of high inten-
sity EGFR staining was associated with biologically aggres-
sive non-small cell lung cancers.
Further patient follow-up will obviously be important in
determining whether intense staining for EGFR and TFR,
combined with a high percentage reactivity with Ki-67
antibody and DNA aneuploidy, will ultimately define a
subset of head and neck cancer patients with a poor clinical
outcome.
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